Cargando…

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples

Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) is not yet performed routinely in the standard care of oncology patients, although it offers a high potential to improve treatment outcome and minimize toxicity. TKIs are perfect candidates for TDM as they show a relatively small...

Descripción completa

Detalles Bibliográficos
Autores principales: Verougstraete, Nick, Stove, Veronique, Verstraete, Alain G., Stove, Christophe P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980857/
https://www.ncbi.nlm.nih.gov/pubmed/35392223
http://dx.doi.org/10.3389/fonc.2022.821807
_version_ 1784681488129720320
author Verougstraete, Nick
Stove, Veronique
Verstraete, Alain G.
Stove, Christophe P.
author_facet Verougstraete, Nick
Stove, Veronique
Verstraete, Alain G.
Stove, Christophe P.
author_sort Verougstraete, Nick
collection PubMed
description Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) is not yet performed routinely in the standard care of oncology patients, although it offers a high potential to improve treatment outcome and minimize toxicity. TKIs are perfect candidates for TDM as they show a relatively small therapeutic window, a wide inter-patient variability in pharmacokinetics and a correlation between drug concentration and effect. Moreover, most of the available TKIs are susceptible to various drug-drug interactions and medication adherence can be checked by performing TDM. Plasma, obtained via traditional venous blood sampling, is the standard matrix for TDM of TKIs. However, the use of plasma poses some challenges related to sampling and stability. The use of dried blood microsamples can overcome these limitations. Collection of samples via finger-prick is minimally invasive and considered convenient and simple, enabling sampling by the patients themselves in their home-setting. The collection of small sample volumes is especially relevant for use in pediatric populations or in pharmacokinetic studies. Additionally, working with dried matrices improves compound stability, resulting in convenient and cost-effective transport and storage of the samples. In this review we focus on the different dried blood microsample-based methods that were used for the quantification of TKIs. Despite the many advantages associated with dried blood microsampling, quantitative analyses are also associated with some specific difficulties. Different methodological aspects of microsampling-based methods are discussed and applied to TDM of TKIs. We focus on sample preparation, analytics, internal standards, dilution of samples, external quality controls, dried blood spot specific validation parameters, stability and blood-to-plasma conversion methods. The various impacts of deviating hematocrit values on quantitative results are discussed in a separate section as this is a key issue and undoubtedly the most widely discussed issue in the analysis of dried blood microsamples. Lastly, the applicability and feasibility of performing TDM using microsamples in a real-life home-sampling context is discussed.
format Online
Article
Text
id pubmed-8980857
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89808572022-04-06 Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples Verougstraete, Nick Stove, Veronique Verstraete, Alain G. Stove, Christophe P. Front Oncol Oncology Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) is not yet performed routinely in the standard care of oncology patients, although it offers a high potential to improve treatment outcome and minimize toxicity. TKIs are perfect candidates for TDM as they show a relatively small therapeutic window, a wide inter-patient variability in pharmacokinetics and a correlation between drug concentration and effect. Moreover, most of the available TKIs are susceptible to various drug-drug interactions and medication adherence can be checked by performing TDM. Plasma, obtained via traditional venous blood sampling, is the standard matrix for TDM of TKIs. However, the use of plasma poses some challenges related to sampling and stability. The use of dried blood microsamples can overcome these limitations. Collection of samples via finger-prick is minimally invasive and considered convenient and simple, enabling sampling by the patients themselves in their home-setting. The collection of small sample volumes is especially relevant for use in pediatric populations or in pharmacokinetic studies. Additionally, working with dried matrices improves compound stability, resulting in convenient and cost-effective transport and storage of the samples. In this review we focus on the different dried blood microsample-based methods that were used for the quantification of TKIs. Despite the many advantages associated with dried blood microsampling, quantitative analyses are also associated with some specific difficulties. Different methodological aspects of microsampling-based methods are discussed and applied to TDM of TKIs. We focus on sample preparation, analytics, internal standards, dilution of samples, external quality controls, dried blood spot specific validation parameters, stability and blood-to-plasma conversion methods. The various impacts of deviating hematocrit values on quantitative results are discussed in a separate section as this is a key issue and undoubtedly the most widely discussed issue in the analysis of dried blood microsamples. Lastly, the applicability and feasibility of performing TDM using microsamples in a real-life home-sampling context is discussed. Frontiers Media S.A. 2022-03-22 /pmc/articles/PMC8980857/ /pubmed/35392223 http://dx.doi.org/10.3389/fonc.2022.821807 Text en Copyright © 2022 Verougstraete, Stove, Verstraete and Stove https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Verougstraete, Nick
Stove, Veronique
Verstraete, Alain G.
Stove, Christophe P.
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
title Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
title_full Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
title_fullStr Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
title_full_unstemmed Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
title_short Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
title_sort therapeutic drug monitoring of tyrosine kinase inhibitors using dried blood microsamples
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980857/
https://www.ncbi.nlm.nih.gov/pubmed/35392223
http://dx.doi.org/10.3389/fonc.2022.821807
work_keys_str_mv AT verougstraetenick therapeuticdrugmonitoringoftyrosinekinaseinhibitorsusingdriedbloodmicrosamples
AT stoveveronique therapeuticdrugmonitoringoftyrosinekinaseinhibitorsusingdriedbloodmicrosamples
AT verstraetealaing therapeuticdrugmonitoringoftyrosinekinaseinhibitorsusingdriedbloodmicrosamples
AT stovechristophep therapeuticdrugmonitoringoftyrosinekinaseinhibitorsusingdriedbloodmicrosamples